Neuroblastoma Treatment
High-risk Neuroblastoma
CommercialMarketed
Key Facts
About Recordati
Founded in 1926 by Giovanni Recordati, this Milan-based pharmaceutical group has evolved from a family pharmacy into a global pharmaceutical force with operations in ~150 countries. The company focuses on both common conditions affecting large populations and rare diseases with limited treatment options, operating through integrated R&D, manufacturing, and commercial capabilities. With a market valuation of approximately €10.5 billion and strong presence in Europe, the company continues expanding its specialty and rare disease portfolio while maintaining its commitment to 'unlocking the full potential of life.'
View full company profileTherapeutic Areas
Other High-risk Neuroblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| SIMBs + Liposomal Doxorubicin (L-Dox) | Advanced Microbubbles | Pre-clinical |